Key result
Aldosterone blockers added to ACE inhibitor or ARB regimens exerted significant antiproteinuric effects in patients with diabetic and nondiabetic nephropathies.
Why the study?
Do aldosterone blockers added to ACEi/ARB regimens improve antiproteinuric effects in patients with diabetic and nondiabetic nephropathies?
Do aldosterone blockers added to ACEi/ARB regimens improve antiproteinuric effects in patients with diabetic and nondiabetic nephropathies?
Answers are grounded in this paper and cite their sources.
Aldosterone blockade added to standard ACEi/ARB therapy shows preliminary promise in reducing proteinuria in chronic kidney disease, warranting larger clinical trials.
Experimental evidence indicates that aldosterone, besides its mineralcorticoid properties, directly contributes to accelerate renal damage through promotion of cell growth, fibrosis and inflammation. As a consequence, attenuation of growth-promoting and fibroproliferative effects of aldosterone might contribute to slow progression of chronic renal injury. Preliminary clinical observations have documented that aldosterone blockers added to angiotensin-converting enzyme inhibitor- and/or angiotensin receptor blocker-based regimens exerted significant antiproteinuric effects in patients with diabetic and nondiabetic nephropathies. Further studies in larger cohorts are now required to definitively address the safety and efficacy of aldosterone antagonism in patients with chronic kidney diseases.
No takes yet. Share an insight, caveat, or question.
Cortinovis et al. (2009) conducted a review in Chronic kidney disease. Aldosterone blockers was evaluated. Aldosterone blockers added to ACE inhibitor or ARB regimens exerted significant antiproteinuric effects in patients with diabetic and nondiabetic nephropathies.
Synapse has enriched 10 related papers. Consider them for comparative context: